MARKET

ARPO

ARPO

Aerpio Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.260
-0.020
-1.56%
Pre Market: 1.260 0 0.00% 08:00 07/06 EDT
OPEN
1.270
PREV CLOSE
1.280
HIGH
1.291
LOW
1.240
VOLUME
676.89K
TURNOVER
--
52 WEEK HIGH
1.530
52 WEEK LOW
0.4200
MARKET CAP
51.14M
P/E (TTM)
-2.7356
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ARPO stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.

EPS

ARPO News

More
Aerpio Pharmaceuticals, Inc. (ARPO) Outpaces Stock Market Gains: What You Should Know
Zacks · 6d ago
Is Aerpio Pharmaceuticals (ARPO) Outperforming Other Medical Stocks This Year?
Zacks · 6d ago
HC Wainwright & Co. Maintains Neutral on Aerpio Pharmaceuticals, Raises Price Target to $1.5
HC Wainwright & Co. maintains Aerpio Pharmaceuticals (NASDAQ:ARPO) with a Neutral and raises the price target from $1 to $1.5.
Benzinga · 06/25 10:49
Aerpio Pharmaceuticals shares are trading higher after the company announced it would initiate its Phase 2 Razuprotafib Glaucoma Trial. UPDATE: Shares have since reversed, now lower.
Benzinga · 06/24 16:26
Aerpio launches mid-stage study of razuprotafib in glaucoma
Seeking Alpha - Article · 06/24 13:28
Aerpio Announces Initiation of 28-Day Phase 2 Razuprotafib Glaucoma Trial
GlobeNewswire · 06/24 13:00
DELL, PLUG among premarket gainers
Seeking Alpha - Article · 06/24 12:14
Aerpio Announces Initiation Of 28-Day Phase 2 Razuprotafib Glaucoma Trial
CINCINNATI, June 24, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases, ARDS
Benzinga · 06/24 12:06

Industry

Biotechnology & Medical Research
+0.68%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About ARPO

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications. Its lead product candidate is AKB-9778. AKB-9778 works by inhibiting VE-PTP, an enzyme that is upregulated in diabetic eye disease and that is responsible for inactivating Tie2. The Company is also developing a bispecific antibody that binds both VEGF and VE-PTP, which is designed to inhibit VEGF activation and activate Tie2. The Company’s pipeline includes the humanized monoclonal antibody, ARP-1536, directed at the same target as subcutaneous AKB-9778.
More

Webull offers kinds of Aerpio Pharmaceuticals Inc stock information, including NASDAQ:ARPO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARPO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARPO stock methods without spending real money on the virtual paper trading platform.